Market Cap (In SEK)
6.75 Million
Revenue (In SEK)
5.14 Million
Net Income (In SEK)
-22.98 Million
Avg. Volume
1.28 Million
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.01-0.161
- PE
- -
- EPS
- -
- Beta Value
- 0.424
- ISIN
- SE0007815428
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Kjell G. Stenberg Ph.D.
- Employee Count
- -
- Website
- https://www.cyxone.com
- Ipo Date
- 2016-06-07
- Details
- Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
More Stocks
-
1555
-
AMSams-OSRAM AG
AMS
-
MOLI
-
CRTG
-
AP
-
9929SEM Holdings Limited
9929
-
BICOBICO Group AB (publ)
BICO
-
600491